The SOPHIE program supports collaborative projects for Ontario-based life science firms in the later stages of commercialization. DiagnaMed can leverage fu...
“The close of the LimFlow acquisition allows us to begin to integrate this exciting technology that is offering new hope to patients suffering from C...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneou...
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an eq...
Claritas, a leader in image enhancement and AI diagnostic solutions has developed pioneering technology for real-time precision detection of conditions in ...
The International Myeloma Foundation (IMF), which leads the Coalition to Improve Access to Cancer Care (CIACC), fervently supports the Cancer Drug Parity A...
Both of these biomarkers are included in the company’s commercially available Precivity™ blood tests, which help healthcare providers determine...
“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...
-Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, an...
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week...
Fragile X and Autism collectively impact over seven million individuals in the United States and Europe. Despite this staggering number, there are currentl...
Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibi...
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid bi...
Under the terms of the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in t...
© 2025 Biopharma Boardroom. All Rights Reserved.
